The survey identifies a range of issues such as the access to health and harm reduction services and the ongoing negative impact of criminalisation, stigma and discrimination on the lives of people who use drugs.
Reprieve and LBHM discuss contradictions between development goals and punitive drug policies, and the negative impact on social, economic and environmental outcomes.
IDPC and TNI argue that the WHO’s recommendations will be an opportunity for African States to further decolonise drug control and strengthen the legal basis for emerging medicinal cannabis programmes.
HRI, SANPUD and Metzineres underscore the importance of alternatives to incarceration and the availability of humane, accessible and non-stigmatising services in prisons and the community.
AFEW International reports that although harm reduction and health organisations are adapting to pandemic restrictions, the continuity of prevention and treatment remains affected.
Transform and MUCD compare different aspects of regulation models in Canadian provinces, including licences, retail stores, age restrictions, prices, home-growing and remaining social inequalities.
Irvine et al. found that take‐home naloxone kits, supervised consumption sites and opioid agonist therapy have been effective in averting overdose deaths in British Columbia.
Unlu et al. argue that the impact of decriminalisation is heavily mediated by contextual factors, including investment in harm reduction and law enforcement involvement.